Skip directly to content

El Descubrimiento del inhibidor de JAK

Fecha: 
Martes, Febrero 7, 2017
Duración: 
25:58
Conferencista: 
Dr. Mark E. Flanagan
 

Referencias: 

Xeljanz. Highlights for Prescribing information 2012. Pfizer Labs.

Witthuhn et al (1994). Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370, 153 – 157.

Vijayakrishnan L  et al .Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci. 32(1):25-34.

van Vollenhoven RF (2009). Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 5(10):531-41.

Taskén K & Aandahl EM (2004). Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 84(1):137-67.

Shuai K & Liu B (2003). Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 3(11):900-11.

Schett, G. et al (2008). How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis & Rheumatism, 58: 2936–2948.

Sanjabi S (2009).  Anti- and Pro-inflammatory Roles of TGF-β, IL-10, and IL-22 In Immunity and Autoimmunity. Curr Opin Pharmacol.  9(4): 447–453. doi:10.1016/j.coph.2009.04.008

Rommel C &Camps M, Ji H (2007). PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 7(3):191-201.

Qiu Y & Kung H. (2000). Signaling network of the Btk family kinases. Oncogene 19, 5651 ± 5661

O’Shea JJ (2013). JAKs and STATs in Immunity, Immunodeficiency, and Cancer. N Engl J Med 368;2

O’Sullivan et al (2007). Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease. Molecular Immunology 44 2497–2506.

Milici A et al (2008). Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Research & Therapy 10:R14 (doi:10.1186/ar2365).

Meyer et al (2010). Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. Journal of Inflammation 2010, 7:41.

McInnes I. & Schett G (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nature Review.

McInnes I (2011). The Pathogenesis of Rheumatoid Arthritis. N Engl J Med.365:2205-19

McInnes I & Liew F ( 2005). Cytokine networks—towards new therapies for rheumatoid arthritis. Nature Clinical Practice. VOL 1  No 1.

Mavers et al (2009). Intracellular Signal Pathways: Potential for Therapies. Curr Rheumatol Rep. 11(5): 378–385.

Kontzias A et al (2012). Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Current Opinion in Pharmacology. 12:464–470

 

https://www.pfizerpro.com.ec/sites/g/files/g10037456/f/201607/XELJANZ-ec...